TuHURA Biosciences Inc. Common Stock (HURA)
Stock · NASDAQ · Health Care
$1.77as of 10/16/2026
Price chart
Active signals
HURA Signal Track Record
How signals performed across all stocks →What HURA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 31 | -8.2% | 45% | September 28, 2026 |
| Bollinger Band Breakdown | 21 | -7.1% | 38% | October 1, 2026 |
| Bollinger Band Breakout | 19 | -2.0% | 47% | August 14, 2026 |
| 200-Day Moving Average TouchActive now | 5 | +4.3% | 60% | October 5, 2026 |
| Any 20-session window (baseline) | -7.5% | 38% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About HURA
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 adminis…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 22
- Website
- tuhurabio.com/
Fundamentals
- 1-day range
- $1.74$1.83
- Market cap
- $134.69M
- P/E (trailing)
- —
- P/E (forward)
- -3.02
- EPS (trailing)
- $-0.54
- Dividend yield
- —
- Beta
- -0.24
- Avg. volume
- 225.1K
Forecasts
5 analyst ratings
TuHURA Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- HURATuHURA Biosciences Inc. Common Stock$1.76▼ 3.83%Market cap $134.69MP/E —$0.41$3.43
- EQEquillium Inc. Common Stock$1.19▼ 9.85%Market cap $134.04MP/E —$0.76$3.54
- VTVTvTv Therapeutics Inc. Class A Common Stock$26.54▼ 3.81%Market cap $136.33MP/E 55.59$19.5$44
- CNTBConnect Biopharma Holdings Limited Ordinary Shares$0.906▲ 0.00%Market cap $137.89MP/E —$0.8501$3.82
- UNCYUnicycive Therapeutics Inc. Common Stock$3.36▼ 6.41%Market cap $138.33MP/E —$3.56$8.74
- OGIOrganigram Global Inc. Common Shares$0.927▼ 0.54%Market cap $139.37MP/E 2.08$1.2$3.09
- KZIAKazia Therapeutics Limited American Depositary Shares$7.25▼ 2.03%Market cap $140.89MP/E —$4.86$17.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| HURA TuHURA Biosciences Inc. Common Stock | $134.69M | — | $1.76 | ▼ 3.83% | $0.41$3.43 |
| EQ Equillium Inc. Common Stock | $134.04M | — | $1.19 | ▼ 9.85% | $0.76$3.54 |
| VTVT vTv Therapeutics Inc. Class A Common Stock | $136.33M | 55.59 | $26.54 | ▼ 3.81% | $19.5$44 |
| CNTB Connect Biopharma Holdings Limited Ordinary Shares | $137.89M | — | $0.906 | ▲ 0.00% | $0.8501$3.82 |
| UNCY Unicycive Therapeutics Inc. Common Stock | $138.33M | — | $3.36 | ▼ 6.41% | $3.56$8.74 |
| OGI Organigram Global Inc. Common Shares | $139.37M | 2.08 | $0.927 | ▼ 0.54% | $1.2$3.09 |
| KZIA Kazia Therapeutics Limited American Depositary Shares | $140.89M | — | $7.25 | ▼ 2.03% | $4.86$17.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- TuHURA Biosciences Secures US Patent For TBS-2025, Entitled ‘Anti-VISTA Antibodies And Uses Thereof’benzinga · 10/13/2026
- TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) TechnologyYahoo · 10/5/2026
- TuHURA Biosciences Receives U.S. Patent For Administration Of DOR AntagonistsBenzinga · 10/5/2026
- TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related CancersYahoo · 9/14/2026
- FDA Gives Clearance To TuHURA Biosciences' IND Application For TBS-2025 VISTA-Inhibiting Antibody For Molecularly Defined Subsets Of AML And Other Blood-Related CancersBenzinga · 9/14/2026
Insider Activity
Insider Actions →- James A. Bianco · May 28, 2026 · Gift150.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 8.89M
- Total value held
- $15.75M
- Institutional holders
- 84
- Unknown2.45M
- Unknown2.07M
- Unknown986.9K
- Unknown607.2K
- Unknown512.9K
- Unknown298.2K
- Unknown211.6K
- Unknown158.0K
- Unknown140.2K
- Unknown104.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
HURA Secures U.S. Patent for DOR Antagonist Delivery
TuHURA Biosciences has been granted a U.S. patent covering the administration of DOR antagonists. The approval protects the company’s delivery technology and could support future drug development or licensing deals. The patent may strengthen HURA’s intellectual property portfolio and provide a competitive edge in the field of opioid receptor research.
HURA Secures U.S. Patent for DOR Antagonist Delivery. TuHURA Biosciences has been granted a U.S. patent covering the administration of DOR antagonists. The approval protects the company’s delivery technology and could support future drug development or licensing deals. The patent may strengthen HURA’s intellectual property portfolio and provide a competitive edge in the field of opioid receptor research.